SCHEMBL342175

SCHEMBL342175

CCCCCCCCCCCCCc1cccc(C(=O)O)c1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BID P55957 3/20 0.63
MCL1 Q07820 3/20 0.63
KAT8 Q9H7Z6 3/20 0.63
PPARA Q07869 3/20 0.63
BCL2L1 Q07817 2/20 0.63
BAK1 Q16611 2/20 0.63
SAE1 Q9UBE0 2/20 0.63
PPARG P37231 2/20 0.63
EP300 Q09472 2/20 0.63
KAT5 Q92993 2/20 0.63
KAT2A Q92830 1/20 0.63
KAT2B Q92831 1/20 0.63
HMGB1 P09429 1/20 0.61
MMP2 P08253 2/20 0.55
F7 P08709 2/20 0.55
F3 P13726 2/20 0.55
KDM4E B2RXH2 1/20 0.55
MAPT P10636 1/20 0.55
ALOX15 P16050 1/20 0.55
ECE1 P42892 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2047267 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL112984 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL168815 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL2044839 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL2046701 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL6435540 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL6436998 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL5272270 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL1003208 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1
SCHEMBL9410786 1.00 BID (0.63) BIDMCL1KAT8PPARABCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1933807-B1 COSMETIC PRODUCT FOR THE TREATMENT OF SCALP CUTRIN OY (FI) 2015-11-04 EP claimed
EP-1176949-B1 LIPID PARTICLES ON THE BASIS OF MIXTURES OF LIQUID AND SOLID LIPIDS AND METHOD FOR PRODUCING SAME PHARMASOL GMBH (DE) 2014-12-10 EP claimed
US-20120321685-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER SOL-GEL TECHNOLOGIES LTD. (IL) 2012-12-20 US claimed
EP-2324812-A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients Sol-Gel Technologies Ltd. (IL) 2011-05-25 EP claimed
US-20050037087-A1 Compositions containing oils having a specific gravity higher than the specific gravity of water SOL-GEL TECHNOLOGIES LTD. (IL) 2005-02-17 US claimed
EP-1446086-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER Sol-Gel Technologies Ltd. (IL) 2004-08-18 EP claimed
JP-2003534249-A 2003-11-18 JP claimed
EP-1335693-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS Sol-Gel Technologies Ltd. (IL) 2003-08-20 EP claimed
WO-2003039510-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER SOL-GEL TECHNOLOGIES LTD. (IL) 2003-05-15 WO claimed
WO-2003034979-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS SOL-GEL TECHNOLOGIES LTD. (IL) 2003-05-01 WO claimed
EP-0987011-B1 Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use OREAL (FR) 2002-07-17 EP claimed
EP-0886517-B1 METHOD FOR REDUCING SKIN OILS AND GREASE UNILEVER PLC (GB) 2002-07-03 EP claimed
US-20020064541-A1 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients SOL-GEL TECHNOLOGIES LTD. (IL) 2002-05-30 US claimed
EP-0881896-B1 SKIN TREATMENT WITH SALICYLIC ACID ESTERS AND RETINOIDS FD MAN INC (US) 2002-05-02 EP claimed
EP-1176949-A2 LIPID PARTICLES ON THE BASIS OF MIXTURES OF LIQUID AND SOLID LIPIDS AND METHOD FOR PRODUCING SAME Pharmasol GmbH (DE) 2002-02-06 EP claimed
WO-2001080823-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TROPICAL ACTIVE INGREDIENTS SOL-GEL TECHNOLOGIES LTD. (IL) 2001-11-01 WO claimed
WO-2000067728-A2 LIPID PARTICLES ON THE BASIS OF MIXTURES OF LIQUID AND SOLID LIPIDS AND METHOD FOR PRODUCING SAME PHARMASOL GMBH (DE) 2000-11-16 WO claimed
EP-4322910-B1 RETINOL OIL FORMULATION DSM IP ASSETS BV (NL) 2026-01-14 EP disclosed
EP-0839840-A2 Novel succinimide compound and method for producing it, lubricating oil additive comprising the compound, and lubricating oil composition comprising the compound for diesel engines IDEMITSU KOSAN COMPANY LIMITED (JP) 1998-05-06 EP disclosed
EP-0807429-A1 Cosmetic composition with retinol unsaturated fatty acid esters UNILEVER PLC (GB) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120321685-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER GNG2, COG5, SQLE BID 4867/4885MCL1 2927/4885KAT8 1256/4885
US-20050037087-A1 Compositions containing oils having a specific gravity higher than the specific gravity of water GNG2, COG5, SQLE BID 4867/4885MCL1 2927/4885KAT8 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.